Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Montana
Clinical trial register · United States · industry-sponsored

Clinical Trials in Montana, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9118 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 06 Oct 2026, 03:16 UTC
9118
Studies in scope
industry-sponsored, all four open statuses
4945
Recruiting now
open to new participants
2189
Lead sponsors
across recruiting studies
Top states
California 5290 Florida 4430 Illinois 2481 Georgia 2368 Arizona 2238
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Merck Sharp & Dohme LLC8 AbbVie3 Novartis Pharmaceuticals2 Pfizer2 Georgiamune Inc1
State
California5290 Florida4430 Illinois2481 Georgia2368 Arizona2238
All 51 states
Target enrolment
to

Trials with a site in Montana

46 of 9118 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer
NCT07310420Advanced Breast Cancer, Early Breast Cancer
DrugZoladex
TerSera Therapeutics LLC
Phase 1
176
Arkansas, District of Columbia, Florida, Georgia, Illinois, Louisiana, Michigan, Montana
2026-10-30
Not yet open
A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity
NCT07845500Obesity, Overweight and/or Obesity, Overweight, Treatment Of Obesity
DrugsBerobenatide·Tirzepatide·Semaglutide
Pfizer
Phase 3
660
Alabama, Florida, Kentucky, Michigan, Missouri, Montana, North Carolina, Ohio
2026-10-01
Recruiting
A Study to Evaluate Safety and Explore Efficacy of New Lipase NHS7108 in Adult Participants With Exocrine Pancreatic Insufficiency.
NCT07559175Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF), Pancreatic Enzyme Abnormality, Pancreatic Diseases
DrugZenpep
Aimmune Nestlé Health Science US R&D, LLC
Phase 2
66
Arizona, Arkansas, California, Florida, Kansas, Maryland, Montana, Ohio
2026-10
Recruiting
Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer
NCT07851025Epithelial Ovarian Cancer
DrugsTorvutatug samrotecan·Bevacizumab
AstraZeneca
Phase 3
950
Florida, Maryland, Montana, Ohio
2026-09-16
Recruiting
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
NCT07623161Myelofibrosis, Anemia
DrugElritercept
Takeda
Phase 3
324
Arizona, California, District of Columbia, Florida, Georgia, Massachusetts, Missouri, Montana
2026-09-10
Recruiting
A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)
NCT07421167Primary Immune Thrombocytopenia (ITP), Primary Evans Syndrome (ES)
DrugsTpo-Ra·Avatrombopag·Romiplostim·Eltrombopag
Novartis Pharmaceuticals
Phase 2
164
Arkansas, Connecticut, Florida, Illinois, Louisiana, Minnesota, Missouri, Montana
2026-08-04
Recruiting
Comparative Self-collection for Cervical Cancer Screening Pivotal Study
NCT07758140HPV, HPV - Anogenital Human Papilloma Virus Infection
Mel Mont Medical
Not applicable
260
Arizona, California, Florida, Idaho, Montana, North Carolina, Texas, Washington
2026-07-09
Recruiting
A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004)
NCT07614984Lipoprotein(a)
DrugsHRS-5346·Enlicitide
Merck Sharp & Dohme LLC
Phase 2
750
Alabama, California, Connecticut, Florida, Maryland, Michigan, Minnesota, Montana
2026-06-30
Recruiting
A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia
NCT07477704Hypercholesterolemia
DrugsPraluent·Alirocumab
Regeneron Pharmaceuticals
Phase 2
420
Alabama, California, Florida, Georgia, Hawaii, Kentucky, Louisiana, Montana
2026-06-17
Recruiting
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
NCT07513376Non-small Cell Lung Cancer
DrugsPembrolizumab Formulated with Berahyaluronidase Alfa·Intismeran autogene
Merck Sharp & Dohme LLC
Phase 3
876
California, Colorado, Connecticut, Illinois, Missouri, Montana, Nebraska, Nevada
2026-05-04
By invitation
Autism Spectrum Disorder (ASD) Neurodevelopmental Disorder With Issues Social Behavior, Communication Issues, GI Dysfunction. Study is Multimodal Interventions Targeting These Pathways With cSVF, Stored MSCs, FMT and Diet Modification. Role of Autoimmunity, Gut-brain Issues, & Issues Examined.
NCT07546942Autism Spectrum Disorder, Autism, Autism Spectral Disorder
Black Tie Medical, Inc.
Phase 1/2
50
Montana
2026-04-30
Recruiting
A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
NCT07409181Systemic Lupus Erythematosus
DrugBI 3000202
Boehringer Ingelheim
Phase 2
405
California, Colorado, Florida, Michigan, Mississippi, Montana, North Carolina, Ohio
2026-04-20
Recruiting
A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice
NCT07556159Asthma
Sanofi
Observational
2,500
Arizona, California, Florida, Georgia, Illinois, Kentucky, Maryland, Montana
2026-04-01
Recruiting
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
NCT07288177Non-small Cell Lung Cancer (NSCLC)
DrugRina-S
Genmab
Phase 2
240
California, District of Columbia, Florida, Georgia, Montana, Nebraska, New Jersey, New York
2026-01-30
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
NCT07059845Ovarian Cancer
DrugsMirvetuximab Soravtansine·Bevacizumab·Carboplatin
AbbVie
Phase 2
400
California, Florida, Kentucky, Louisiana, Maine, Massachusetts, Michigan, Montana
2025-11-13
Recruiting
A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
NCT07175285Systemic Lupus Erythematosus (SLE)
Bristol-Myers Squibb
Observational
223
California, Florida, Georgia, Illinois, Maryland, Michigan, Montana, New Jersey
2025-10-08
Recruiting
A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)
NCT07133633Radiographic Axial Spondyloarthritis
DrugTulisokibart
Merck Sharp & Dohme LLC
Phase 2
315
Arizona, California, Florida, Illinois, Maryland, Missouri, Montana, Nebraska
2025-09-26
Recruiting
External Therapy for Tinnitus Management
NCT07017998Tinnitus, Tinnitus, Subjective
Restorear Devices LLC
Not applicable
80
Montana
2025-07-16
Recruiting
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
NCT06991114Refractory Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathies (IIMs), Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA
Artiva Biotherapeutics, Inc.
Phase 2
90
Alabama, Arizona, California, Florida, Georgia, Illinois, Iowa, Montana
2025-07-09
By invitation
Virtuos Bone Graft in Lumbar Fusion
NCT06686017Degenerative Disc Disease
Orthofix Inc.
Observational
150
Indiana, Michigan, Montana, North Carolina, South Carolina, Texas, Virginia
2025-06-05
Recruiting
Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia
NCT06953869Insomnia Disorder
DrugTasimelteon
Vanda Pharmaceuticals
Phase 3
420
Alabama, Arizona, California, Florida, Georgia, Illinois, Massachusetts, Montana
2025-04-21
Active, closed
A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)
NCT06864169Gastrointestinal Cancer
DrugR-DXd
Merck Sharp & Dohme LLC
Phase 2
160
Connecticut, District of Columbia, Florida, Montana, New Jersey, Ohio, Virginia, Wisconsin
2025-04-01
Active, closed
Evaluating SUI-100™, A Non-Invasive Device for the Treatment of Stress Urinary Incontinence
NCT06862648Stress Urinary Incontinence (SUI)
Acoustic Wave Cell Therapy, Inc.
Not applicable
130
Arizona, Florida, Idaho, Kansas, Montana, Nevada, Ohio, Texas
2025-03-25
Recruiting
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
NCT06797635Breast Neoplasms, Breast Cancer
DrugsPatritumab deruxtecan·Doxorubicin Hydrochloride·Epirubicin·Adriamycin
Merck Sharp & Dohme LLC
Phase 2
372
California, Illinois, Montana, Oregon, Tennessee, Texas, Virginia
2025-03-20
Active, closed
A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT06291220Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugsABBV-453·Obinutuzumab
AbbVie
Phase 1
4
California, Montana, North Carolina, Texas
2025-01-27
Recruiting
A Single-arm, Pivotal Study to Evaluate Acute Device and Technical Success of the CGuard Prime Carotid Stent System When Used in Conjunction to the ENROUTE Transcarotid Neuroprotection System in Patients Undergoing Carotid Artery Stenting Via the Transcarotid Artery Revascularization Approach
NCT06653387Carotid Artery Diseases
InspireMD
Not applicable
50
California, Indiana, Minnesota, Missouri, Montana, New York, Ohio
2024-11-20
Active, closed
A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)
NCT06660173Type 2 Diabetes Mellitus (T2DM)
DrugMaridebart cafraglutide
Amgen
Phase 2
409
Alabama, California, Florida, Georgia, Illinois, Louisiana, Michigan, Montana
2024-11-07
Recruiting
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
NCT06345729Non-small Cell Lung Cancer
DrugsCalderasib·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
348
California, Connecticut, Florida, Illinois, Missouri, Montana, New Jersey, New York
2024-05-24
Recruiting
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
NCT06425926Melanoma Stage IV, Solid Tumor
Georgiamune Inc
Phase 1/2
117
Arizona, California, Massachusetts, Montana, New York, Ohio, Tennessee, Virginia
2024-05-09
Active, closed
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
NCT06297603Type 2 Diabetes
DrugRetatrutide
Eli Lilly and Company
Phase 3
320
Alabama, Arizona, California, Florida, Georgia, Idaho, Kansas, Montana
2024-03-15
Recruiting
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
NCT06162221Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer, Lung Cancer Stage IV, Advanced Solid Tumor, Cancer
DrugsElironrasib·RMC-9805·Cetuximab·Pemetrexed
Revolution Medicines, Inc.
Phase 1/2
616
Arizona, California, Colorado, District of Columbia, Florida, Massachusetts, Michigan, Montana
2024-01-18
Active, closed
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
NCT06105632Advanced or Metastatic Breast Cancer
DrugsExemestane·Everolimus·Fulvestrant
Pfizer
Phase 2
333
California, District of Columbia, Montana, Texas
2024-01-09
Recruiting
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
NCT05947851Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Chronic Lymphocytic, Small-Cell Lymphoma, Lymphoma, Small Lymphocytic
DrugsNemtabrutinib·Venetoclax·Rituximab
Merck Sharp & Dohme LLC
Phase 3
735
Arkansas, California, Florida, Indiana, Maryland, Mississippi, Missouri, Montana
2023-08-08
By invitation
A Clinical Trial to Investigate Long-term Safety, Tolerability, and Efficacy of Weekly Subcutaneous Doses With TransCon CNP in Children and Adolescents With Achondroplasia
NCT05929807Achondroplasia
Ascendis Pharma Growth Disorders A/S
Phase 2/3
140
Arkansas, Colorado, Delaware, Minnesota, Montana, New York, Texas, Wisconsin
2023-06-21
Active, closed
Camera Qualification Study
NCT05808699Diabetic Retinopathy
Digital Diagnostics, Inc.
Observational
626
California, Florida, Mississippi, Montana, North Dakota, Texas
2023-03-03
Active, closed
A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids
NCT05653219Primary Immune Thrombocytopenia
DrugsEltrombopag·Ianalumab
Novartis Pharmaceuticals
Phase 3
152
Arizona, Colorado, Illinois, Massachusetts, Michigan, Montana, New York
2023-02-02
Recruiting
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT05254743Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma
DrugsPirtobrutinib·Ibrutinib
Loxo Oncology, Inc.
Phase 3
737
California, Florida, Louisiana, Maryland, Montana, Pennsylvania, South Carolina, Tennessee
2022-07-22
Active, closed
Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma
NCT04674683Unresectable or Metastatic Melanoma, Progressive Brain Metastasis
DrugsChidamide·Nivolumab
HUYABIO International, LLC.
Phase 3
450
California, Florida, Indiana, Kentucky, Maryland, Missouri, Montana, North Carolina
2021-08-12
Active, closed
Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)
NCT04956692Non-Small Cell Lung Cancer
DrugsAbraxane·Paraplatin·Taxol·Nab-paclitaxel
Merck Sharp & Dohme LLC
Phase 3
531
Arkansas, California, Florida, Indiana, Kentucky, Missouri, Montana, New York
2021-08-05
Active, closed
A Study of Guselkumab in Participants With Active Psoriatic Arthritis
NCT04882098Arthritis, Psoriatic
DrugGuselkumab
Janssen Research & Development, LLC
Phase 3
1,054
Alabama, Arizona, California, Florida, Maryland, Michigan, Missouri, Montana
2021-06-17
Active, closed
TTVR Early Feasibility Study
NCT04433065Tricuspid Regurgitation
Medtronic Cardiovascular
Not applicable
150
Alabama, Arizona, California, Connecticut, Georgia, Michigan, Minnesota, Montana
2020-10-20
Active, closed
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
NCT04291105Melanoma, Head and Neck Squamous Cell Carcinoma, Colo-rectal Cancer
DrugsVSV-IFNβ-NIS·Cemiplimab
Vyriad, Inc.
Phase 2
87
California, Connecticut, Florida, Louisiana, Minnesota, Montana, New York, Ohio
2020-04-24
Recruiting
Adipose-Derived Biocellular Regenerative Therapy for Osteoarthritis
NCT04238143Osteoarthritis, Osteo Arthritis Knee, Osteo Arthritis Shoulders, Osteoarthritis of Multiple Joints
Healeon Medical Inc
Not applicable
100
California, Montana
2020-01-10
Active, closed
Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors
NCT03821935Advanced Solid Tumors Cancer
DrugsLivmoniplimab·Budigalimab
AbbVie
Phase 1
364
Arkansas, California, Connecticut, Florida, Indiana, Michigan, Missouri, Montana
2019-02-21
Active, closed
Performance of MOTO Medial® Unicompartmental Knee Arthroplasty
NCT03211663Knee Osteoarthritis, Knee Arthritis, Knee Pain Chronic
Medacta USA
Observational
269
Florida, Kentucky, Montana, North Carolina, Pennsylvania
2017-10-09
Active, closed
Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)
NCT02477696Chronic Lymphocytic Leukemia
DrugsIbrutinib·Acalabrutinib
Acerta Pharma BV
Phase 3
533
Arizona, California, Florida, Georgia, Illinois, Kansas, Minnesota, Montana
2015-07-28
Rows per page Showing 1–46 of 46
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 6 October 2026. https://priyalifescience.com/clinical-trials-usa/state/montana

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,118 studies in total at the last sync on 06 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 46 of those studies with a site in Montana.

How many clinical trials are recruiting in Montana?

26 of the 46 studies on this page are recruiting new participants as of the 06 Oct 2026, 03:16 UTC sync. A further 1 have not yet opened recruitment, 16 are active but closed to new participants, and 3 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Montana), 46 studies
PhaseStudiesRecruitingShare
Phase 2141030.4%
Phase 314730.4%
Not applicable6413%
Observational5210.9%
Phase 1316.5%
Phase 1/2326.5%
Phase 2/3102.2%

Most active sponsors

Lead sponsors with the most studies (Montana)
Lead sponsorStudiesRecruiting
Merck Sharp & Dohme LLC86
AbbVie31
Novartis Pharmaceuticals21
Pfizer20
Acerta Pharma BV10
Acoustic Wave Cell Therapy, Inc.10
Aimmune Nestlé Health Science US R&D, LLC11
Amgen10
Artiva Biotherapeutics, Inc.11
Ascendis Pharma Growth Disorders A/S10
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.